Related Experiment Video
Updated: Feb 4, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
Published on: October 17, 2025
Genetic mechanisms of target antigen loss in CAR19 therapy of acute lymphoblastic leukemia
Elena J Orlando1, Xia Han2, Catherine Tribouley2
1Novartis Institutes for BioMedical Research, Cambridge, MA, USA. elena.orlando@novartis.com.
Abstract:
We identified genetic mutations in CD19 and loss of heterozygosity at the time of CD19- relapse to chimeric antigen receptor (CAR) therapy. The mutations are present in the vast majority of resistant tumor cells and are predicted to lead to a truncated protein with a nonfunctional or absent transmembrane domain and consequently to a loss of surface antigen. This irreversible loss of CD19 advocates for an alternative targeting or combination CAR approach.
Insights
Genetic mutations in CD19 cause resistance to CAR therapy by eliminating the surface antigen. This irreversible loss necessitates alternative chimeric antigen receptor (CAR) strategies or combination therapies for effective treatment.
Area of Science:
- Immunology
- Genetics
- Oncology
Background:
- Chimeric antigen receptor (CAR) therapy shows promise for hematologic malignancies.
- Relapse due to antigen loss remains a significant challenge in CAR therapy.
Purpose of the Study:
- To investigate the mechanisms of CD19 loss in patients relapsing after CAR therapy.
- To identify genetic alterations responsible for CD19 antigen escape.
Main Methods:
- Genetic sequencing of tumor cells from patients with CD19-negative relapse.
- Analysis of mutations affecting the CD19 gene and protein structure.
Main Results:
- Identified genetic mutations and loss of heterozygosity in the CD19 gene in relapsed tumor cells.
- Mutations predicted to result in a truncated, nonfunctional CD19 protein lacking a surface transmembrane domain.
- Confirmed widespread presence of these mutations in resistant tumor cell populations.
Conclusions:
- Irreversible loss of the CD19 target antigen is a key mechanism of relapse.
- Alternative CAR targets or combination CAR approaches are needed to overcome CD19 loss and improve therapeutic outcomes.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Line Loss
Line loss impacts power delivery efficiency in a balanced three-phase circuit. The symmetry in such a circuit simplifies the...
What is Genetic Engineering?
Reducing Line Loss
With a step-up transformer at the source, the voltage is increased, thereby reducing the current in the transmission lines since power loss in...
Genetics of Speciation
Types of Genetic Transfer Between Organisms

